| Popis: |
M Janelle Cambron-Mellott,1 Jaromir Mikl,2 Joana E Matos,1 Jennifer G Erensen,2 Kathleen Beusterien,1 Marc J Cataldo,2 Bernadette Hallissey,1 Gregory W Mattingly3– 5 1Kantar Health, New York, NY, USA; 2Purdue Pharma L.P./Adlon Therapeutics, L.P., Stamford, CT, USA; 3Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA; 4Midwest Research Group, St. Charles, MO, USA; 5St. Charles Psychiatric Associates, St. Charles, MO, USACorrespondence: M Janelle Cambron-MellottKantar Health, 3 World Trade Center, 175 Greenwich Street, 35th Floor, New York, NY, 10007, USATel +1 212 706 3961Email janelle.cambron-mellott@kantar.comBackground and Objective: Treatment for attention deficit hyperactivity disorder (ADHD) requires a multifaceted approach including psychosocial interventions and pharmacological treatment. This study evaluates preferences for specific attributes associated with different long-acting stimulant treatment among US adults with ADHD.Methods: Patients completed an online, cross-sectional survey, incorporating a discrete choice experiment to assess preferences for attributes.Results: Analyses included 200 adults with ADHD (mean age 33.0 years; 60% self-reporting moderate severity); the mean (SD) Adult ADHD Self-Report Scale-v1.1 score was 45.9 (12.4). Overall, patients valued speed of onset most and risk of rebound least. Three population groups with distinct preferences were identified: side effect-driven (n=69, 35%), quick onset-driven (n=47, 24%) and quick onset and long duration-driven (n=84, 42%).Conclusion: This study shows differences in how adults with ADHD value and assess benefit-risk trade-offs when considering the desired attributes of stimulant treatments, highlighting the importance of patient-physician shared decision-making to optimize the desired benefits of individualized treatment.Keywords: attention deficit hyperactivity disorder, choice behavior, CNS stimulants, discrete choice experiment, patient preference |
